ArticleHarm reduction journal2023
'We don't live in a harm reduction world, we live in a prohibition world': tensions arising in the design of drug alerts.
Article in Harm reduction journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Responding to medetomidine in Philadelphia: narrative summary of the public health response to a new psychoactive substance.Addiction science & clinical practice · 2026Article
- Exploring the Utility and Appropriateness of Dose Thresholds for Issuing of Public Drug Alerts on High-Dose MDMA: A Qualitative Study.Drug and alcohol review · 2026Article
- Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.Current topics in behavioral neurosciences · 2026Review
- Mapping experiences of workplace stigma and discrimination within the lived-living experience of illicit drug use and bloodborne virus peer workforce: a scoping review.Harm reduction journal · 2025Article
- Opioid-related deaths in Northern Ontario in the early COVID-19 pandemic period.Canadian journal of public health = Revue canadienne de sante publique · 2025Article
- Responding to reports of nitazene toxicity in Australia.The Medical journal of Australia · 2025Article
- Is fentanyl in everything? Examining the unexpected occurrence of illicit opioids in British Columbia's drug supply.Harm reduction journal · 2025Article
- Development, dissemination and community response towards the first community notice regarding misrepresented illicit anabolic-androgenic steroids in circulation in Australia.Drug and alcohol review · 2025Article
- Syringe services program staff and participant perspectives on changing drug consumption behaviors in response to xylazine adulteration.Harm reduction journal · 2024Article
- Protective or potentially harmful? Altering drug consumption behaviors in response to xylazine adulteration.Research square · 2024Article
- Beyond a spec: assessing heterogeneity in the unregulated opioid supply.Harm reduction journal · 2024Article
- A qualitative assessment of key considerations for drug checking service implementation.Harm reduction journal · 2023Article
- Correction: 'We don't live in a harm reduction world, we live in a prohibition world': tensions arising in the design of drug alerts.Harm reduction journal · 2023Article
- Co-designing drug alerts for health and community workers for an emerging early warning system in Victoria, Australia.Harm reduction journal · 2023Article
- Digital transformation of the harm reduction sector-"Here4UScotland" a case study of a virtual supervised consumption.Digital healthArticle
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug alerts designed for health and community workforces have potential to avert acute harms associated with unpredictable illicit drug markets, by preparing workers to respond to unusual drug-related events, and distribute information to service users. However, the design of such alerts is complicated by diverse needs of individuals, and broader socio-political contexts. Here, we discuss the tensions that arose in the process of co-designing drug alert templates with health and community workers.
methodsWe conducted five in-depth digital co-design workshops with 31 workers employed in alcohol and other drug and urgent care settings. Our approach to analysis was informed by Iterative Categorisation and reflexive thematic analysis methods.
resultsWe identified five key tensions. First, there is a need to provide comprehensive information to meet the information needs of a diverse group of workers with varying knowledge levels, while also designing alerts to be clear, concise, and relevant to the work of individuals. Second, it is important that alerts do not create 'information overload'; however, it is also important that information should be available to those who want it. Third, alert design and dissemination must be perceived to be credible, to avoid 'alert scepticism'; however, credibility is challenging to develop in a broader context of criminalisation, stigmatisation, and sensationalism. Fourth, alerts must be carefully designed to achieve 'intended effects' and avoid unintended effects, while acknowledging that it is impossible to control all potential effects. Finally, while alerts may be intended for an audience of health and community workers, people who use drugs are the end-users and must be kept front of mind in the design process.
conclusionsThe co-design process revealed complexities in designing drug alerts, particularly in the context of stigmatised illicit drug use, workforce diversity, and dissemination strategies. This study has highlighted the value of developing these important risk communication tools with their target audiences to ensure that they are relevant, useful, and impactful. The findings have informed the development of our drug alert prototypes and provide local context to complement existing best-practice risk-communications literature.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.